Content
Save 40% when you buy the entire hair kit. See the kit
Minoxidil is one of the most popular hair loss treatments out there. If you’ve started noticing the signs of female hair loss, the good news is that minoxidil is safe for women.
In fact, minoxidil is the only FDA-approved medication for the treatment of female pattern hair loss (also called FPHL) as well as male pattern baldness. Plus, the American Academy of Dermatology recommends topical minoxidil to treat hair loss in women.
Commonly sold under the brand name Rogaine®, topical minoxidil is typically a dermatologist’s first line of defense in the treatment of hair loss. It can be used to treat many types of hair loss, including female pattern hair loss, alopecia areata, and telogen effluvium.
Read on to learn more about using minoxidil for female hair loss. We’ll discuss the safety of minoxidil for women, different minoxidil formulations, and how it can help you regrow new hair.
Content
Yes — absolutely. Minoxidil is one of the most researched hair loss treatments on the market, and numerous studies have shown that it works safely and effectively for both men and women as a hair loss treatment. Phew.
Both topical and oral minoxidil are safe for women.
Minoxidil isn’t just a hair loss medication, though. Oral minoxidil started out as a treatment for high blood pressure, which was used in both women and men — quite safely, we might add.
Minoxidil works because it’s a vasodilator, which means that it relaxes and widens your blood vessels. When it does this to your scalp, it boosts blood flow to the hair follicles, which means your follicles can get the nutrients they need to grow hair.
It also seems to put your hair follicles in the anagen phase, or growth phase, of the hair growth cycle. This means your hair grows for a longer period of time.
We dive deeper in our guide to minoxidil for female hair loss if you want to learn more.
Topical minoxidil, which is available over the counter, comes in two concentrations: 2% and 5%. Usually, 2% minoxidil comes as a liquid solution, while 5% minoxidil is available as a foam.
Both minoxidil formulations are safe for women to use. Both are also effective for hair regrowth.
When it comes to comparing 2% minoxidil solution to 5% topical foam, a couple of clinical trials have indicated that the higher-strength dosage may offer more promising results.
An older 48-week placebo-controlled study looked at the effects of 5% topical minoxidil and 2% topical minoxidil in 381 women who had androgenetic alopecia (that is, female pattern hair loss).
The women in the study applied minoxidil twice a day, and at the end of the 48 weeks, researchers found that hair regrowth and scalp coverage increased relative to prescription strength. The 5% group experienced the best results, but the 2% topical solution group still experienced superior results to the placebo group.
A different randomized clinical study found that using 5% minoxidil foam once a day worked just as well as 2% minoxidil solution twice a day, and that both seemed to improve hair growth.
In summary, both work well. It’s a good idea to consider whether you’re more comfortable using foam or drops. While foam can be easier to spread, drops can provide a more targeted treatment.
Since minoxidil 5% is stronger than minoxidil 2%, you might assume that the former causes more intense side effects.
The randomized clinical trial mentioned above found that 5% minoxidil foam seemed to cause fewer side effects than 2% minoxidil solution. But this might be because the foam was only applied once, while the solution was applied twice a day. It could also be because of propylene glycol — an ingredient that is found in the solution but is not found in the foam.
In the other 48-week study, though, in which the 2% and 5% strengths were both topical solutions and the 5% strength wasn’t topical foam, the stronger formulation was associated with a higher chance of itching and irritation.
The possible side effects of topical minoxidil include:
Scalp irritation, dermatitis or rash at the application site
Scalp itchiness
Dry, flaking scalp
A slight burning sensation
Skin rash
It’s also possible to experience an allergic reaction, contact dermatitis, or unwanted hair growth (hypertrichosis)
When you first start using minoxidil, you might experience increased hair shedding for a few weeks. Don’t worry about this — it just means your hair follicles are getting ready to enter the growth phase. It typically takes 3 to 6 months of consistent use to see visible results.
Check out our guide to the side effects of minoxidil for women for a full list. Learn more about minoxidil while breastfeeding if that’s a concern for you.
If topical minoxidil isn’t working for you, or if the side effects are uncomfortable, you might consider other hair loss treatment options.
For example, you could try:
Low-dose oral minoxidil, which can also boost new hair growth
Hair growth supplements, like our biotin gummies, which are packed with hair-loving vitamins
Quality hair care products that work for your hair type, like a volumizing shampoo to improve the appearance of limp, thin hair
Spironolactone, which is effective for female pattern baldness
Topical finasteride and minoxidil spray, which has been developed for post-menopausal hair loss
Gentle hair styling methods, which can help you avoid hair breakage and damaged hair
If you have severe hair loss and room in your budget, you might consider an in-office treatment like hair transplant surgery or platelet-rich plasma therapy for hair loss. While costly, these treatments can produce some impressive results.
So, can women use Rogaine? In summary, yes. Minoxidil is both safe and effective for women.
Here’s what you need to know:
Minoxidil is safe for women. Minoxidil is approved by the FDA and recommended by the American Academy of Dermatology for female pattern baldness.
Both minoxidil 2% and minoxidil 5% are effective and safe. But both can produce side effects in some people — for example, a dry scalp or itchiness.
There are many hair loss treatments for women. If topical minoxidil isn’t working for you, you can try oral minoxidil, hair loss shampoos, or hair growth supplements.
Not sure where to start? Get personalized medical advice from a healthcare provider. This can help you figure out which treatment options may be right for you.
We can help you book an online consultation with a licensed healthcare professional — get started with an easy online quiz.
Hims & Hers has strict sourcing guidelines to ensure our content is accurate and current. We rely on peer-reviewed studies, academic research institutions, and medical associations. We strive to use primary sources and refrain from using tertiary references. See a mistake? Let us know at [email protected]!
Dr. Knox Beasley is a board-certified dermatologist specializing in hair loss. Dr. Beasley obtained his Bachelor of Science from the United States Military Academy at West Point, NY, and he subsequently attended medical school at Tulane University School of Medicine in New Orleans, LA.
Dr. Beasley first began doing telemedicine during his dermatology residency in 2013 with the military in San Antonio, TX, helping to diagnose dermatologic conditions in soldiers all over the world. Dr. Beasley is board certified by the American Board of Dermatology, and is a Fellow of the American Academy of Dermatology.
Originally from Nashville, TN, Dr. Beasley currently lives in North Carolina and enjoys spending time outdoors (with sunscreen, of course) with his wife and two children in his spare time.
Bachelor of Science, Life Sciences. United States Military Academy.
Doctor of Medicine. Tulane University School of Medicine
Dermatology Residency. San Antonio Uniformed Services Health Education Consortium
Board Certified. American Board of Dermatology
Wilson, L. M., Beasley, K. J., Sorrells, T. C., & Johnson, V. V. (2017). Congenital neurocristic cutaneous hamartoma with poliosis: A case report. Journal of cutaneous pathology, 44(11), 974–977. https://onlinelibrary.wiley.com/doi/10.1111/cup.13027
Banta, J., Beasley, K., Kobayashi, T., & Rohena, L. (2016). Encephalocraniocutaneous lipomatosis (Haberland syndrome): A mild case with bilateral cutaneous and ocular involvement. JAAD case reports, 2(2), 150–152. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867906/
Patterson, A. T., Beasley, K. J., & Kobayashi, T. T. (2016). Fibroelastolytic papulosis: histopathologic confirmation of disease spectrum variants in a single case. Journal of cutaneous pathology, 43(2), 142–147. https://onlinelibrary.wiley.com/doi/10.1111/cup.12569
Beasley, K., Panach, K., & Dominguez, A. R. (2016). Disseminated Candida tropicalis presenting with Ecthyma-Gangrenosum-like Lesions. Dermatology online journal, 22(1), 13030/qt7vg4n68j. https://pubmed.ncbi.nlm.nih.gov/26990472/
Kimes, K., Beasley, K., & Dalton, S. R. (2015). Eruptive milia and comedones during treatment with dovitinib. Dermatology online journal, 21(9), 13030/qt8kw141mb. https://pubmed.ncbi.nlm.nih.gov/26437285/
Miladi, A., Thomas, B. C., Beasley, K., & Meyerle, J. (2015). Angioimmunoblastic t-cell lymphoma presenting as purpura fulminans. Cutis, 95(2), 113–115. https://pubmed.ncbi.nlm.nih.gov/25750965/
Beasley K, Dai JM, Brown P, Lenz B, Hivnor CM. (2013). Ablative Fractional Versus Nonablative Fractional Lasers – Where Are We and How Do We Compare Differing Products?. Curr Dermatol Rep, 2, 135–143. https://link.springer.com/article/10.1007/s13671-013-0043-0
Siami P, Beasley K, Woolen S, Zahn J. (2012). A retrospective study evaluating the efficacy and tolerability of intra-abdominal once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. UroToday Int J, June 5(3), art 26. https://www.urotoday.com/volume-5-2012/vol-5-issue-3/51132-a-retrospective-study-evaluating-the-efficacy-and-tolerability-of-intra-abdominal-once-yearly-histrelin-acetate-subcutaneous-implants-in-patients-with-advanced-prostate-cancer.html
Siami P, Beasley K. (2012). Dutasteride with As-Needed Tamsulosin in Men at Risk of Benign Prostate Hypertrophy Progression. UroToday Int J, Feb 5(1), art 93. https://www.urotoday.com/volume-5-2012/vol-5-issue-1/48691-dutasteride-with-as-needed-tamsulosin-in-men-at-risk-of-benign-prostatic-hypertrophy-progression.html